We found that pretreatment of cultured neurons with the CaM kinase II/IV inhibitor KN-93 blocks Golgi fragmentation by bicuculline treatment. 10 DIV, = 8; 14 DIV, = 9; 17 DIV, = 17). Golgi Fragmentation also Results from Neuronal Hyperactivity. Knowing that Golgi fragmentation results from neuronal hyperexcitability, we wondered if hyperactivity also causes fragmentation of the Golgi complex. Mature cultured neurons (21 DIV) were treated with bicuculline for 1C2 d, then bicuculline was removed (Fig. 2= 10; Bic, 1 d, = 7; Bic, 3 d, = 6; APV, 1 d, ICA-110381 = 9; APV, 3d, = 7; TTX+Bic, 1 d, = 5). For Bic, 1 d, < 0.1. A similar observation ICA-110381 of Golgi fragmentation was detected for neurons after removal of APV (Fig. 2region of the Golgi, TGN38 is located in the Golgi. For TGN38, the number of Golgi fragments was 14 (IR = 11C17) after 1 d bicuculline treatment, 16 (IR = 11C22) for 1 d after APV withdrawal Mouse monoclonal to Plasma kallikrein3 (APV, 3 d), and 4 (IR = 2C5) for untreated control (Fig. 3= 10; Bic, 1 d, = 9; APV, 1 d, = 8; APV, 3d, = 7). Golgi Fragmentation from Hyperactivity Is Reversible. The experiments shown in Figs. 2 and ?and33 suggest that the Golgi fragmentation is reversible upon return to normal neuronal activity. Additionally, we checked the neurons during Golgi fragmentation conditions (both during bicuculline and after APV washout) for signs of apoptosis and found the neurons remain healthy with intact mitochondria and nuclei (Fig. S2). Nonetheless, we wanted to observe the reversibility of the Golgi fragmentation, so we turned to live cell time-lapse imaging of cultured hippocampal neurons cotransfected with fluorescently labeled Golgi enzyme Mgat2 (Mgat2CEGFP) and myristoylated Td-Tomato (to visualize neuron morphology). The somatic region of individual neurons was imaged before and 1 d after treatment with bicuculline. With addition of bicuculline, Mgat2CEGFP localization showed some fragmentation (Fig. 4shows two example neurons and Fig. 4shows a mock-treated control). After 1 d of bicuculline treatment, the medium was removed and replaced with preconditioned normal medium. Following return to normal medium, the neurons were imaged 2 d later to observe reversal of the Golgi fragmentation. The summary data of individual neurons (Fig. 4= 12) and control (black, = 4) neurons. Activity-Dependent Golgi Fragmentation Requires CaM Kinase Activation. Knowing increased neuronal activity leads to an increase in intracellular calcium, we hypothesized that a calcium-dependent pathway may lead to the Golgi fragmentation. We found that pretreatment of cultured neurons with the CaM kinase II/IV inhibitor KN-93 blocks Golgi fragmentation by bicuculline treatment. Using the same conditions of mature cultured hippocampal neurons as used in Fig. 1, KN-93 was added 20 min before addition of bicuculline (Fig. 5and = 10; Bic, 1 d, = 7; KN-93+Bic, 1 d, = 5; Bic, 3 d, = 6). (and = 11; OA, 1 d, = 10; OA, 2 d, = 9). (and Fig. S1) are color-coded (only for ease of visualization of fragments) with spectrum coloring of red (largest fragment) to violet (for the smallest). Live Time-Lapse Imaging. Cotransfected neurons (Mgat2-EGFP and myristoylated Td-Tomato) were imaged by ICA-110381 epifluorescence microscopy at 15 DIV. Then at least half of the conditioned medium was removed and saved, and bicuculline (20 M) was added to the cells. After 1 d, the same neurons were imaged before removal of the bicuculline-containing medium and replacement with the conditioned medium. Two days later the cells were imaged again. The numbers of distinct fragments of Mgat2CEGFP signal were counted and compared with mock-treated cultures. Data Analysis. Results are reported as median and IR; means and SD were not used, as the datasets are not normally distributed. Comparisons of group medians were performed with nonparametric KruskalCWallis with Dunns posttest using Prism 5 (GraphPad Software), with differences considered significant at < 0.05 (*< 0.05, **< 0.01, ***< 0.001 in all graphs). Supplementary Material Supporting Information: Click here to view. Acknowledgments This work was supported by a National Institutes of Health National Research Service Award postdoctoral fellowship (to D.A.T.) and National Institute of Mental Health Grant MH065334. Y.N.J. and L.Y.J. are Howard Hughes ICA-110381 Medical Institute investigators. Footnotes The authors declare no conflict of interest. This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1220978110/-/DCSupplemental..
Recent Posts
- Interestingly, 8C11 neutralizes HEV genotype I particularly, however, not the additional genotypes
- The IgG concentration was evaluated using immunoturbidimetry, while IgG subclass levels by the nephelometric method
- Bottom sections: the tiniest equipped SSTI possibility among SSTI situations was 78% and the best SSTI possibility among the handles was 29%, teaching an obvious separation from the equipped infection status based on the measured IgG amounts
- This antibody property could also offer an explanation for the actual fact the fact that HspB5L-P44 had not been seen in previous studies
- Significance relative to placebo\treated group was tested with the MannCWhitney and and showed no signs of a superagonistic effect 15, 37
Recent Comments
Archives
- January 2025
- December 2024
- November 2024
- October 2024
- September 2024
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
Categories
- Orexin Receptors
- Orexin, Non-Selective
- Orexin1 Receptors
- ORL1 Receptors
- Ornithine Decarboxylase
- Orphan 7-TM Receptors
- Orphan 7-Transmembrane Receptors
- Orphan G-Protein-Coupled Receptors
- Orphan GPCRs
- OT Receptors
- Other Acetylcholine
- Other Adenosine
- Other Apoptosis
- Other ATPases
- Other Calcium Channels
- Other Cannabinoids
- Other Channel Modulators
- Other Dehydrogenases
- Other Hydrolases
- Other Ion Pumps/Transporters
- Other Kinases
- Other MAPK
- Other Nitric Oxide
- Other Nuclear Receptors
- Other Oxygenases/Oxidases
- Other Peptide Receptors
- Other Pharmacology
- Other Product Types
- Other Proteases
- Other RTKs
- Other Synthases/Synthetases
- Other Tachykinin
- Other Transcription Factors
- Other Transferases
- Other Wnt Signaling
- OX1 Receptors
- OXE Receptors
- Oxidative Phosphorylation
- Oxoeicosanoid receptors
- Oxygenases/Oxidases
- Oxytocin Receptors
- P-Glycoprotein
- P-Selectin
- P-Type ATPase
- P-Type Calcium Channels
- p14ARF
- p160ROCK
- P2X Receptors
- P2Y Receptors
- p38 MAPK
- p53
- p56lck
- p60c-src
- p70 S6K
- p75
- p90 Ribosomal S6 Kinase
- PAC1 Receptors
- PACAP Receptors
- PAF Receptors
- PAO
- PAR Receptors
- Parathyroid Hormone Receptors
- PARP
- PC-PLC
- PDE
- PDGFR
- PDK1
- PDPK1
- Peptide Receptor, Other
- Peptide Receptors
- Peroxisome-Proliferating Receptors
- PGF
- PGI2
- Phosphatases
- Phosphodiesterases
- Phosphoinositide 3-Kinase
- Phosphoinositide-Specific Phospholipase C
- Phospholipase A
- Phospholipase C
- Phospholipases
- Phosphorylases
- Photolysis
- PI 3-Kinase
- PI 3-Kinase/Akt Signaling
- PI-PLC
- PI3K
- Pim Kinase
- Pim-1
- PIP2
- Pituitary Adenylate Cyclase Activating Peptide Receptors
- PKA
- PKB
- PKC
- PKD
- PKG
- PKM
- PKMTs
- PLA
- Plasmin
- Platelet Derived Growth Factor Receptors
- Platelet-Activating Factor (PAF) Receptors
- Uncategorized